CODEXIS, INC.: insider trades · United States · SEC (Form 4)

About CODEXIS, INC.

Codexis, Inc. (ticker: CDXS) is a U.S.-based company listed on the NASDAQ in the United States. It is a specialized enzyme-engineering and biomanufacturing technology company focused on enabling more efficient production of complex therapeutics. Founded in 2002 and headquartered in Redwood City, California, Codexis built its early reputation on its proprietary CodeEvolver® platform, which is used to discover, optimize, and tailor enzymes for demanding industrial applications. Over time, the company has shifted its strategic center of gravity toward higher-value life-science opportunities, especially pharmaceutical manufacturing, nucleic-acid synthesis, and other advanced bioprocessing applications. Codexis’ business model is best understood as a technology platform model rather than a traditional drug-development model. The company develops and licenses engineered enzymes and process solutions designed to improve yield, scalability, selectivity, and sustainability in manufacturing. Its main commercial focus today is the ECO Synthesis™ Manufacturing Platform, an enzymatic route intended to support scalable production of RNAi therapeutics, including siRNA. The company also continues to serve small-molecule pharmaceutical manufacturing and selected diagnostics and research applications through custom enzyme solutions. In practical terms, Codexis aims to solve process bottlenecks for pharmaceutical customers by replacing or improving upon legacy chemical methods with more efficient biocatalytic routes. From a competitive standpoint, Codexis operates in a narrow but technically demanding niche. Its success depends on intellectual property, scientific know-how, speed of development, and the ability to translate enzyme performance into industrial-scale economics. The company competes with other biocatalysis providers, custom synthesis companies, and emerging RNA-manufacturing technologies. Codexis differentiates itself by emphasizing better yields, lower energy use, reduced waste, and manufacturing flexibility—factors that matter to large pharma companies, biotechs, and contract development and manufacturing organizations (CDMOs). Recent company updates point to stronger commercial momentum in RNA manufacturing. In 2025, Codexis announced a $37.8 million supply assurance agreement with Merck, which helped extend its cash runway through 2027. In early 2026, the company disclosed an agreement to manufacture 50 grams of siRNA using its ECO Synthesis platform for a therapeutic candidate in preclinical development. That kind of customer activity is important because it suggests that Codexis is moving beyond proof-of-concept into more tangible commercial engagement. For investors, the company remains a small-cap, high-risk, innovation-driven name, with upside tied to partnership execution, technology adoption, and continued validation of its enzymatic manufacturing platform in the pharmaceutical supply chain.